Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 6:48 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 1,626 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cancer Genetics Clear all

Conditions: Melanoma, Young Adult
Interventions: MC1R Genetic Testing, Skin Cancer Education, UV Photo; Diagnostic Test · Other · Device
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Atopic Dermatitis
Interventions: Pimecrolimus; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 8,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Kidney Cancer, Leukemia, Lymphoma, Myelodysplastic Syndromes, Neuroblastoma, Sarcoma
Interventions: filgrastim, allogeneic bone marrow transplantation; Biological · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Up to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 2
States / cities: Nashville, Tennessee • Seattle, Washington

Conditions: Kidney Cancer, Leukemia, Lymphoma, Neurotoxicity, Peripheral Neuropathy, Sarcoma
Interventions: Glutamine, Placebo; Drug · Other
Lead sponsor: Columbia University; Other
Eligibility: 5 Years to 21 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: BRAF or NRAS Mutant Metastatic Melanoma
Interventions: MEK162; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2023
U.S. locations: 10
States / cities: Fayetteville, Arkansas • Tampa, Florida • Portland, Oregon + 3 more

Conditions: Breast Cancer
Interventions: Active Provider Intervention; Other
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older · Female only
Enrollment: 3,780 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Neurofibromatosis Type 1
Interventions: AlgometRx Nociometer(R); Device
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Year to 120 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland

Conditions: Breast Cancer
Interventions: Tamoxifen; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Gastrointestinal Stromal Tumor
Interventions: mutation analysis, polymorphism analysis, laboratory biomarker analysis; Genetic · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer
Interventions: Gedatolisib, Palbociclib, Letrozole, Fulvestrant; Drug
Lead sponsor: Celcuity Inc; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 41
States / cities: Birmingham, Alabama • Corona, California • Fountain Valley, California + 17 more

Conditions: Hereditary Cancer Syndrome
Interventions: Natera empower comprehensive hereditary cancer panel, Obstetrical carrier screening; Device
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Adenocarcinoma, Prostate Neoplasms, Prostate Cancer, Renal Cell Carcinoma, Von Hippel Lindau Disease
Interventions: EM Tracking; Device
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 3,894 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Cancer
Interventions: suberoylanilide hydroxamic acid (SAHA, Vorinostat), tamoxifen citrate (Tamoxifen); Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 8
States / cities: San Francisco, California • Boynton Beach, Florida • Orlando, Florida + 5 more

Conditions: Pancreatic Cancer
Interventions: Synthetic Human Secretin; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 35 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Lung Cancer, Single Primary Lung Cancer, Second Primary Lung Cancer
Interventions: Blood draw and Questionnaires; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Genetic Predisposition, Cancer
Interventions: DNA or RNA Sequencing; Genetic
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Chronic Granulomatous Disease, Crohn'S-like IBD, Inflammatory Bowel Disease (IBD)
Interventions: Infliximab; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 10 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Angiofibroma of Face, Tuberous Sclerosis
Interventions: Sirolimus 0.2%, Sirolimus 0.4%, Placebo ointment; Drug
Lead sponsor: Aucta Pharmaceuticals, Inc; Industry
Eligibility: 2 Years to 21 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 7
States / cities: Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 4 more

Conditions: Neurofibromatosis Type 1
Interventions: HLX-1502; Drug
Lead sponsor: Healx Limited; Industry
Eligibility: 12 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 14
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 10 more

Conditions: Endometrial Cancer, Lynch Syndrome, Screening, Early Detection of Cancer
Interventions: Menstrual cup use; Device
Lead sponsor: Jessica D. St. Laurent, MD; Other
Eligibility: 18 Years and older · Female only
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Tuberous Sclerosis
Interventions: JASPER; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 6 Months to 40 Months
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 2
States / cities: Los Angeles, California • Boston, Massachusetts

Conditions: Neurofibromatosis
Interventions: Questionnaires; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cancer
Interventions: anti-thymocyte globulin, rituximab, clofarabine, stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Not listed
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Telomeric 22Q13 Monosomy Syndrome, Tuberous Sclerosis, Hamartoma Syndrome, Multiple, Fragile X Syndrome, Angelman Syndrome, Rett Syndrome, Chromosome 15Q, Partial Deletion, Creatine Deficiency, X-linked
Interventions: Functional Behavioral Training (FBT), Positive Parenting Strategies-Treatment as Usual; Behavioral · Other
Lead sponsor: Rush University Medical Center; Other
Eligibility: 2 Years to 12 Years
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

Risk Information and Skin-cancer Education for Undergraduate Prevention

10 Year Registry of Children (Ages 2-17 Years) With Eczema That Have Used Pimecrolimus

Donor Bone Marrow Transplant in Treating Young Patients With Cancer or a Non-Cancerous Disease

Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors

A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

Cluster Randomized Trial Comparing Interventions to Enhance Genetic Counseling Among Breast Cancer Patients

A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems Using Pupillometry in Participants With Neurofibromatosis Type 1 (NF1)

A Pilot Study of Varying Doses of Tamoxifen in the Setting of Genetic Polymorphisms of CYP2D6

Study of Tumor Samples in Patients Undergoing Treatment for Gastrointestinal Stromal Tumors on Clinical Trial ACOSOG-Z9001

A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer

Feasibility Trial of Combination of Obstetrical Carrier Screening and Hereditary Cancer Screening

Use of Tracking Devices to Locate Abnormalities During Invasive Procedures

Phase II Trial of SAHA & Tamoxifen for Patients With Breast Cancer

Secretin (ChiRhoStim) Pancreas Perfusion for Pancreatic Adenocarcinoma

DNA Repair and Genetic Susceptibility to Lung Cancer

Genetic Investigation of Cancer Predisposition

Infliximab to Treat Crohn'S-like Inflammatory Bowel Disease in Chronic Granulomatous Disease

Topical Sirolimus Ointment for Cutaneous Angiofibromas in Subjects With Tuberous Sclerosis Complex

A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1

Menstrual Cup for Early Endometrial Cancer Detection in Lynch Syndrome

JASPER Early Intervention for Tuberous Sclerosis

Relationship Between Psychosocial Factors, Health Literacy, Quality of Life and Satisfaction With Medical Visits in Adults With NF

Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant

Web Intervention for Parents of Youth With Genetic Syndromes (WINGS)